CA2761074A1 - Pyrazolopyrimidines 4-substituees pouvant etre employees en tant qu'inhibiteurs de pkc-theta - Google Patents

Pyrazolopyrimidines 4-substituees pouvant etre employees en tant qu'inhibiteurs de pkc-theta Download PDF

Info

Publication number
CA2761074A1
CA2761074A1 CA2761074A CA2761074A CA2761074A1 CA 2761074 A1 CA2761074 A1 CA 2761074A1 CA 2761074 A CA2761074 A CA 2761074A CA 2761074 A CA2761074 A CA 2761074A CA 2761074 A1 CA2761074 A1 CA 2761074A1
Authority
CA
Canada
Prior art keywords
independently
compound
halogen
optionally
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2761074A
Other languages
English (en)
Inventor
Juan-Miguel Jimenez
Andrew Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CA2761074A1 publication Critical patent/CA2761074A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2761074A 2010-05-05 2010-05-05 Pyrazolopyrimidines 4-substituees pouvant etre employees en tant qu'inhibiteurs de pkc-theta Abandoned CA2761074A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/033711 WO2011139273A1 (fr) 2010-05-05 2010-05-05 Pyrazolopyrimidines 4-substituées pouvant être employées en tant qu'inhibiteurs de pkc-thêta

Publications (1)

Publication Number Publication Date
CA2761074A1 true CA2761074A1 (fr) 2011-11-10

Family

ID=42288734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2761074A Abandoned CA2761074A1 (fr) 2010-05-05 2010-05-05 Pyrazolopyrimidines 4-substituees pouvant etre employees en tant qu'inhibiteurs de pkc-theta

Country Status (6)

Country Link
EP (1) EP2566866A1 (fr)
JP (1) JP2013525481A (fr)
CN (1) CN102471342A (fr)
AU (1) AU2010352577A1 (fr)
CA (1) CA2761074A1 (fr)
WO (1) WO2011139273A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2016183071A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Composés hétéro-tricycliques substitués et utilisation de ces composés pour le traitement du cancer
WO2017027717A1 (fr) 2015-08-12 2017-02-16 Incyte Corporation Composés de pyrimidine fusionnés bicycliques utilisés en tant qu'inhibiteurs de tam
WO2017035366A1 (fr) * 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
CN108137607B (zh) 2015-08-26 2021-04-06 缆图药品公司 适用于治疗与ntrk相关的病症的化合物和组合物
CN108431008A (zh) 2015-11-19 2018-08-21 蓝图药品公司 可用于治疗与ntrk相关的病症的化合物和组合物
SG11201808582RA (en) 2016-03-28 2018-10-30 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
PT3687996T (pt) 2017-09-27 2022-01-21 Incyte Corp Sais de derivados de pirrolotriazina úteis como inibidores de tam
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
CN110833559A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗急性肺损伤致肺纤维化的用途
BR112023022883A2 (pt) 2021-05-06 2024-01-23 Exscientia Ai Ltd Moduladores de pkc-teta
JP2024517861A (ja) 2021-05-06 2024-04-23 エクセンシア・エイアイ・リミテッド ＰＫＣ－θモジュレーター

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898243A (zh) * 2003-12-23 2007-01-17 诺瓦提斯公司 二环杂环类p－38激酶抑制剂
EP1814885A4 (fr) * 2004-11-23 2009-12-16 Us Therapeutics Inc Reddy Nouveaux composes bicycliques heterocycliques, leur procede de preparation et compositions les contenant
GB0608175D0 (en) * 2006-04-25 2006-06-07 Astex Therapeutics Ltd Pharmaceutical Compounds
WO2009073300A1 (fr) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated Dérivés de [1h-pyrazolo[3,4-b]pyridin-4-yl]-phényle ou -pyridin-2-yle en tant qu'inhibiteurs de la protéine kinase c-thêta
CN101981037B (zh) * 2008-01-30 2013-09-04 吉宁特有限公司 吡唑并嘧啶pi3k抑制剂化合物及使用方法
AU2009266806A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators

Also Published As

Publication number Publication date
CN102471342A (zh) 2012-05-23
EP2566866A1 (fr) 2013-03-13
JP2013525481A (ja) 2013-06-20
WO2011139273A1 (fr) 2011-11-10
AU2010352577A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
US9029546B2 (en) Pyrazolopyridine kinase inhibitors
US8541445B2 (en) Pyrazolopyridines
US8563576B2 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
US20120165368A1 (en) Pyrazolopyridine kinase inhibitors
CA2761074A1 (fr) Pyrazolopyrimidines 4-substituees pouvant etre employees en tant qu'inhibiteurs de pkc-theta
US20120071494A1 (en) Pyrazolopyridine kinase inhibitors
AU2011209644A1 (en) Pyrazolopyridine kinase inhibitors
EP2313372A1 (fr) Inhibiteurs d aminopyridine kinase
US8895740B2 (en) Pyrazolopyrazine kinase inhibitors
US20120172379A1 (en) 4 substituted pyrazolopyrimidines
CA2787363A1 (fr) Inhibiteurs des kinases a base de pyrazolopyrimidine
AU2015201376A1 (en) Pyrazolopyridine kinase inhibitors

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20140506